Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01004978 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 30, 2009
Results First Posted : February 17, 2023
Last Update Posted : February 17, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hepatocellular Carcinoma Unresectable Hepatocellular Carcinoma | Drug: Cisplatin Drug: Doxorubicin Drug: LC bead Drug: Mitomycin Other: Placebo Administration Drug: Sorafenib | Phase 3 |
PRIMARY OBJECTIVE:
I. To compare progression-free survival (PFS) of chemoembolization alone to sorafenib (sorafenib tosylate) in combination with chemoembolization.
SECONDARY OBJECTIVES:
I. To compare overall survival (OS) of chemoembolization alone to sorafenib in combination with chemoembolization.
II. To evaluate extra-hepatic versus intra-hepatic patterns of failure. III. To determine the rates of toxicity related to sorafenib in combination with chemoembolization.
TERTIARY OBJECTIVES:
I. To analyze the pharmacogenetic and pharmacokinetic properties of sorafenib including angiogenesis, monooxygenases, polymorphisms and multidrug resistance (MDR).
II. Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) secondary imaging objective: site versus (vs.) central evaluation of PFS.
III. To determine the inter-reader concordance for response characterization at four and eight months by the European Association for the Study of Liver (EASL) criteria.
IV. To determine the value of objective tumor response at four and eight months by the EASL criteria to predict PFS (by Response Evaluation Criteria in Solid Tumors [RECIST]) and OS.
V. To evaluate the effects of intra-hepatic vs. extra-hepatic progression on OS.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive sorafenib tosylate at 400 mg orally (PO) twice daily (BID) in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo transarterial chemoembolization (TACE) comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm A.
MAINTENANCE THERAPY: After completion of chemoembolization, patients receive sorafenib tosylate or placebo as in Arm A and B in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 years.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 235 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion |
| Actual Study Start Date : | October 28, 2009 |
| Actual Primary Completion Date : | February 11, 2021 |
| Estimated Study Completion Date : | June 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm A (sorafenib and TACE)
Patients receive sorafenib tosylate at 400mg PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (this option may only be utilized for patients registered prior to addendum #3); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising LC bead and doxorubicin. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: Cisplatin
Given IV; undergo trans arterial chemoembolisation (TACE)
Other Names:
Drug: Doxorubicin Given IV; undergo TACE
Other Names:
Drug: LC bead Given IV; undergo TACE Drug: Mitomycin Given IV; undergo TACE
Other Names:
Drug: Sorafenib Given PO
Other Names:
|
|
Active Comparator: Arm B (placebo and TACE)
Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm A.
|
Drug: Cisplatin
Given IV; undergo trans arterial chemoembolisation (TACE)
Other Names:
Drug: Doxorubicin Given IV; undergo TACE
Other Names:
Drug: LC bead Given IV; undergo TACE Drug: Mitomycin Given IV; undergo TACE
Other Names:
Other: Placebo Administration Given PO |
- Progression-free Survival (PFS) [ Time Frame: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years ]
PFS is defined to be the time from randomization to progression or death without evidence of progression. For cases without documentation of progression, follow-up will be censored at the date of last disease assessment without progression, unless death occurs within 4 months following the date last known progression-free, in which case the death will be counted as an event.
Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.
- Overall Survival (OS) [ Time Frame: Assessed every 3 months for 2 years and then every 6 months for 2 years ]Overall survival (OS) is defined as time from randomization to death from any cause, censoring cases who had not died at the date last known alive.
- Progression-free Survival (PFS) Among Patients With Extra-hepatic Progression [ Time Frame: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years ]
PFS is defined to be the time from randomization to progression or death without evidence of progression.
Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.
For patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic. Patients with both intra- and extra-hepatic progression were considered as having extra-hepatic progression. This analysis was performed among patients with extra-hepatic progression.
- Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression [ Time Frame: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years ]
PFS is defined to be the time from randomization to progression or death without evidence of progression.
Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.
For patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic. This analysis was performed among patients with intra-hepatic progression.
- Pharmacogenetic and Pharmacokinetic Properties of Sorafenib Including Angiogenesis, Monooxygenases, Polymorphisms and Multidrug Resistance Mutation (MDR) [ Time Frame: Assessed at baseline, days 1, 8 and 15 of cycle 1 sorafenib, 3-5 days prior to 2nd and 3rd TACE ]This analysis will be performed across a few ECOG-ACRIN studies of sorafenib to evaluate the association between genotypes that are related with sorafenib activity and clinical outcomes.
- Inter-reader Concordance for Response by EASL (European Association for the Study of the Liver) Criteria [ Time Frame: at 4 months and 8 months Assessed at 4 months and 8 months following initial chemoembolization ]Response was determined using the European Association for the Study of the Liver (EASL) criteria, which was recommended as an alternative to RECIST for grading therapeutic response of advanced hepatocellular carcinoma (HCC). The EASL criteria use the longest dimension of enhancing tumor as the primary metric for gauging tumor response. The Kappa statistics will be applied to assess agreement between readers.
- Association Between Objective Tumor Response by EASL Criteria and PFS as Well as OS [ Time Frame: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years ]
PFS is defined to be the time from randomization to progression or death without evidence of progression. For cases without documentation of progression, follow-up will be censored at the date of last disease assessment without progression, unless death occurs within 4 months following the date last known progression-free, in which case the death will be counted as an event.
Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.
OS is defined as time from randomization to death or date last known alive. Response is assessed at 4 and 8 months by EASL criteria.
- To Evaluate the Effects of Intra-hepatic vs. Extra-hepatic Progression on OS. [ Time Frame: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years ]
Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.
For patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic.
OS is defined as the time from randomization to death or date last known alive.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients must have a diagnosis of hepatocellular carcinoma by at least one criterion listed below:
- Histologically confirmed
- Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion > 2 cm with early enhancement and delayed enhancement washout regardless of alpha-feto protein levels (AFP)
- AFP > 400 ng/mL AND evidence of at least one solid liver lesion > 2 cm regardless of specific imaging characteristics on CT or MRI
- Patients must have hepatocellular carcinoma (HCC) limited to the liver
- Portal lymphadenopathy is permitted for patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) - as lymphadenopathy is commonly associated with hepatitis unrelated to malignancy
- Staging CT of the chest and CT or MRI of the abdomen and pelvis must have been completed within 4 weeks of study registration
- Patients must have measurable disease constituting < 50% of liver parenchyma within 4 weeks of registration
- Patients may have been treated with RFA in the past, but no sooner than 4 weeks before study registration
- Patients may have undergone previously attempted curative liver resection
- Branch portal vein invasion by tumor is permitted
- Patients must have Child-Pugh score of A or B7 within 4 weeks prior to study registration
- Serum total bilirubin =< 2.0 mg/dL
- Alkaline phosphatase < 5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 x ULN
- Serum creatinine =< 1.5 mg/dL
- Platelet count >= 50,000/mm^3
-
Patients must meet New York Heart Association functional classification I or II defined as:
- Class I - patients with no limitation of activities; they suffer no symptoms from ordinary activities
- Class II - patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion
- Patients must have an ECOG performance status of 0 or 1
- Patients must have a life expectancy of at least 3 months
- Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception
- Patient must be able to swallow pills, as study medications cannot be crushed
Exclusion Criteria:
- Clinical or radiographic evidence of extrahepatic HCC
- Ascites detectable on physical examination
- Candidates for curative resection, orthotopic liver transplantation, or radiofrequency ablation (RFA)
- Prior brachytherapy such as yttrium-90 microsphere
- Prior sorafenib, chemoembolization, or systemic chemotherapy including cytotoxic agents or molecularly targeted agents
- Patients with main portal vein invasion by tumor
- Evidence of bleeding diathesis or active gastrointestinal bleeding
- Clinical signs of heart failure
- Human immunodeficiency virus (HIV) positive
-
Other uncontrolled intercurrent illnesses excluding HBV or HCV, including, but not limited to: uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/addictive disorders that would limit compliance with study requirements
- Uncontrolled hypertension is defined as optimally treated baseline blood pressure that exceeds 150/90 mm Hg
- Patients must not be taking cytochrome P450 enzyme inducing drugs
- Women must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
- Allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01004978
Show 281 study locations
| Study Chair: | Jean-Francois Geschwind, M.D. | Johns Hopkins University/Sidney Kimmel Cancer Center |
Documents provided by National Cancer Institute (NCI):
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT01004978 |
| Other Study ID Numbers: |
NCI-2011-01981 NCI-2011-01981 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) CDR0000657952 E1208 ( Other Identifier: ECOG-ACRIN Cancer Research Group ) E1208 ( Other Identifier: CTEP ) U10CA180820 ( U.S. NIH Grant/Contract ) U10CA021115 ( U.S. NIH Grant/Contract ) |
| First Posted: | October 30, 2009 Key Record Dates |
| Results First Posted: | February 17, 2023 |
| Last Update Posted: | February 17, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy. |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Unresectable Hepatocellular Carcinoma chemoembolization double-blind |
|
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases Cisplatin Doxorubicin |
Liposomal doxorubicin Sorafenib Mitomycins Mitomycin Antineoplastic Agents Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protein Kinase Inhibitors Alkylating Agents Nucleic Acid Synthesis Inhibitors |